Your session is about to expire
What is Cosopt
TimololThe Generic name of this drug
Treatment SummaryDorzolamide is a medication used to treat eye conditions such as open-angle glaucoma and ocular hypertension. It works by blocking an enzyme that helps regulate the fluid pressure and ion balance in the eyes. Unlike oral carbonic anhydrase inhibitors, Dorzolamide has minimal effects on acid-base and electrolyte levels, as well as few systemic side effects. It was first released in 1995 and is available as both a stand-alone drug (Trusopt) and a combination drug with Timolol (Cosopt PF).
Timopticis the brand name
Cosopt Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Timoptic
Timolol
1978
167
Effectiveness
How Cosopt Affects PatientsDorzolamide is a medication that lowers pressure in the eye. It is used to treat open-angle glaucoma or ocular hypertension. When combined with other eye medications, Dorzolamide can have a stronger effect on reducing pressure in the eye. This medicine usually starts working within two hours after it is used.
How Cosopt works in the bodyDorzolamide is used to treat ocular hypertension and glaucoma. It works by reducing the amount of fluid produced in the eye, which lowers the intraocular pressure. This drug specifically targets an enzyme called Carbonic Anhydrase II which helps produce bicarbonate ions in the ciliary process of the eye. By inhibiting this enzyme, Dorzolamide reduces sodium and fluid transport, resulting in less fluid and lower intraocular pressure. When intraocular pressure is reduced, it prevents blood flow restrictions and keeps the optic nerve from getting damaged, which would cause vision loss.
When to interrupt dosage
The suggested dosage of Cosopt is contingent upon the diagnosed condition, such as neodynium yttrium aluminum garnet laser posterior capsulotomy, Ocular Hypertension and Increased Intra Ocular Pressure (IOP). The dosage is a function of the administration method (e.g. Solution - Ophthalmic or Solution / drops) outlined in the table below.Condition
Dosage
Administration
Migraine
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
, Ophthalmic, Solution, Solution - Ophthalmic, Oral, Tablet, Tablet - Oral, Solution / drops, Solution / drops - Ophthalmic, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Suspension, Suspension - Ophthalmic, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
Migraine Disorders
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
, Ophthalmic, Solution, Solution - Ophthalmic, Oral, Tablet, Tablet - Oral, Solution / drops, Solution / drops - Ophthalmic, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Suspension, Suspension - Ophthalmic, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
insufficient response to beta-blockers
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
, Ophthalmic, Solution, Solution - Ophthalmic, Oral, Tablet, Tablet - Oral, Solution / drops, Solution / drops - Ophthalmic, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Suspension, Suspension - Ophthalmic, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
requiring adjunctive or replacement therapy
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
, Ophthalmic, Solution, Solution - Ophthalmic, Oral, Tablet, Tablet - Oral, Solution / drops, Solution / drops - Ophthalmic, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Suspension, Suspension - Ophthalmic, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
inadequate response to other therapeutic measures
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
, Ophthalmic, Solution, Solution - Ophthalmic, Oral, Tablet, Tablet - Oral, Solution / drops, Solution / drops - Ophthalmic, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Suspension, Suspension - Ophthalmic, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
Open-angle glaucoma
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
, Ophthalmic, Solution, Solution - Ophthalmic, Oral, Tablet, Tablet - Oral, Solution / drops, Solution / drops - Ophthalmic, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Suspension, Suspension - Ophthalmic, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
Glaucoma
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
, Ophthalmic, Solution, Solution - Ophthalmic, Oral, Tablet, Tablet - Oral, Solution / drops, Solution / drops - Ophthalmic, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Suspension, Suspension - Ophthalmic, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
Open Angle Glaucoma
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
, Ophthalmic, Solution, Solution - Ophthalmic, Oral, Tablet, Tablet - Oral, Solution / drops, Solution / drops - Ophthalmic, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Suspension, Suspension - Ophthalmic, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
Ocular Hypertension
5.0 mg/mL, , 5.0 mg, 10.0 mg, 20.0 mg, 2.5 mg/mL, 6.8 mg/mL, 6.83 mg/mL, 2.56 mg/mL, 5.12 mg/mL, 0.5 %, 0.25 %, 3.4 mg/mL, 0.1 mg/mL
, Ophthalmic, Solution, Solution - Ophthalmic, Oral, Tablet, Tablet - Oral, Solution / drops, Solution / drops - Ophthalmic, Solution, gel forming, extended release, Solution, gel forming, extended release - Ophthalmic, Liquid, Liquid - Ophthalmic, Suspension / drops, Suspension / drops - Ophthalmic, Suspension, Suspension - Ophthalmic, Solution, gel forming / drops, Solution, gel forming / drops - Ophthalmic
Warnings
Cosopt ContraindicationsCondition
Risk Level
Notes
Lung Diseases, Obstructive
Do Not Combine
Sinus Bradycardia
Do Not Combine
Shock, Cardiogenic
Do Not Combine
Atrioventricular Block
Do Not Combine
Asthma
Do Not Combine
Heart Failure
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Timolol may interact with Pulse Frequency
Common Cosopt Drug Interactions
Drug Name
Risk Level
Description
4-Bromo-2,5-dimethoxyphenethylamine
Major
The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Timolol.
4-Methoxyamphetamine
Major
The therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Timolol.
Abediterol
Major
Timolol may decrease the bronchodilatory activities of Abediterol.
Adrafinil
Major
The therapeutic efficacy of Adrafinil can be decreased when used in combination with Timolol.
Agrostis gigantea pollen
Major
The risk of a hypersensitivity reaction to Agrostis gigantea pollen is increased when it is combined with Timolol.
Cosopt Toxicity & Overdose RiskThe lowest toxic dose of dorzolamide in rats is 1927mg/kg and 1320mg/kg in mice, when taken orally. In the event of an overdose, patients may experience electrolyte imbalances, acidosis, and changes in the central nervous system. Appropriate care should be taken and the patient’s potassium and pH levels should be monitored.
Cosopt Novel Uses: Which Conditions Have a Clinical Trial Featuring Cosopt?
34 active clinical trials are currently underway to assess the potential of Cosopt in providing relief for Ocular Hypertension, Increased Intra Ocular Pressure (IOP) and Open Angle Glaucoma.Condition
Clinical Trials
Trial Phases
Ocular Hypertension
13 Actively Recruiting
Phase 3, Phase 4, Phase 1, Phase 2, Not Applicable
requiring adjunctive or replacement therapy
0 Actively Recruiting
inadequate response to other therapeutic measures
0 Actively Recruiting
Migraine Disorders
1 Actively Recruiting
Phase 3
Migraine
50 Actively Recruiting
Phase 4, Not Applicable, Phase 2, Phase 1, Phase 3, Early Phase 1
Glaucoma
0 Actively Recruiting
insufficient response to beta-blockers
0 Actively Recruiting
Open-angle glaucoma
38 Actively Recruiting
Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 1
Open Angle Glaucoma
12 Actively Recruiting
Phase 3, Not Applicable, Phase 2, Phase 4, Phase 1
Cosopt Reviews: What are patients saying about Cosopt?
5Patient Review
11/27/2009 This medication was prescribed to me by my optometrist when my eye pressure readings suddenly skyrocketed. Within a week and a half, it had dropped back down to the normal range. I've been using it regularly since then with no issues.
5Patient Review
4/6/2013 I experienced some leg pain while taking this medication.
5Patient Review
7/15/2014 The drops caused my eyes to burn.
5Patient Review
1/16/2010 I've been using this product for a few years now and have always been really pleased with the results.
4Patient Review
1/20/2009 Blurred vision is a very annoying side effect. I spent a lot of money on medical testing for tia's but I feel the blurred vision was from the medication.
Patient Q&A Section about cosopt
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What type of drug is Cosopt?
"COSOPT contains two different types of medicine: dorzolamide hydrochloride, an ophthalmic carbonic anhydrase inhibitor, and timolol maleate, a beta-blocker."
Answered by AI
What are the side effects of cosopt PF eye drops?
"If you experience any of the following side effects, tell your doctor or pharmacist promptly: Temporary blurred vision, temporary burning/stinging/itching/redness of the eye, watery eyes, dry eyes, feeling as if something is in the eye, sensitivity of eyes to light, strange taste in the mouth, or headache."
Answered by AI
What is the generic name for Cosopt?
"Cosopt pairs the drug timolol with another medication, dorzolamide. Your doctor may prescribe this combination drug if timolol alone is not sufficiently treating your high eye pressure or glaucoma."
Answered by AI
What is Cosopt eye drops used for?
"COSOPT is a medication used to lower the pressure in the eye in the treatment of glaucoma. It is used when beta-blocker eyedrop medicine used alone is not adequate."
Answered by AI